Intratumoral T cells have a differential impact on FDG-PET parameters in follicular lymphoma.
Journal
Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425
Informations de publication
Date de publication:
22 06 2021
22 06 2021
Historique:
received:
16
12
2020
accepted:
03
04
2020
entrez:
22
6
2021
pubmed:
23
6
2021
medline:
25
6
2021
Statut:
ppublish
Résumé
Data on the prognostic impact of pretherapy 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) in follicular lymphoma (FL) is conflicting. The predictive utility of pretherapy total metabolic tumor volume (TMTV) and maximum standardized uptake value (SUVmax) on outcome appears to vary between regimens. Chemoimmunotherapies vary in the extent of T-cell depletion they induce. The role of intratumoral T cells on pretherapy FDG-PET parameters is undefined. We assessed pretherapy FDG-PET parameters and quantified intratumoral T cells by multiple methodologies. Low intratumoral T cells associated with approximately sixfold higher TMTV, and FL nodes from patients with high TMTV showed increased malignant B-cell infiltration and fewer clonally expanded intratumoral CD8+ and CD4+ T-follicular helper cells than those with low TMTV. However, fluorescently labeled glucose uptake was higher in CD4+ and CD8+ T cells than intratumoral B cells. In patients with FDG-PET performed prior to excisional biopsy, SUVmax within the subsequently excised node associated with T cells but not B cells. In summary, TMTV best reflects the malignant B-cell burden in FL, whereas intratumoral T cells influence SUVmax. This may contribute to the contradictory results between the prognostic role of different FDG-PET parameters, particularly between short- and long-term T-cell-depleting chemoimmunotherapeutic regimens. The impact of glucose uptake in intratumoral T cells should be considered when interpreting pretherapy FDG-PET in FL.
Identifiants
pubmed: 34156439
pii: S2473-9529(21)00344-X
doi: 10.1182/bloodadvances.2020004051
pmc: PMC8270658
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2644-2649Informations de copyright
© 2021 by The American Society of Hematology.
Références
Semin Cancer Biol. 2014 Feb;24:23-32
pubmed: 23978491
Blood. 2021 May 13;137(19):2704-2707
pubmed: 33512481
Eur J Nucl Med Mol Imaging. 2018 Jul;45(7):1142-1154
pubmed: 29460024
Haematologica. 2020 Dec 17;Online ahead of print:
pubmed: 33327711
Clin Cancer Res. 2017 Apr 1;23(7):1820-1828
pubmed: 27649554
Am J Hematol. 2013 Apr;88(4):273-6
pubmed: 23460351
Ann Oncol. 2017 Sep 1;28(9):2094-2106
pubmed: 28430865
Clin Cancer Res. 2020 Oct 1;26(19):5217-5231
pubmed: 32631956
Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):328-54
pubmed: 25452219
Blood Adv. 2018 Apr 10;2(7):807-816
pubmed: 29636326
Oncotarget. 2017 May 29;8(37):61425-61439
pubmed: 28977875
Blood. 2021 May 27;137(21):2869-2880
pubmed: 33728464
Haematologica. 2020 Jun;105(6):1593-1603
pubmed: 31537685
Haematologica. 2007 Feb;92(2):184-90
pubmed: 17296567
J Biochem Biophys Methods. 2005 Sep 30;64(3):207-15
pubmed: 16182371
J Clin Oncol. 2019 Dec 1;37(34):3300-3309
pubmed: 31461379
Leuk Lymphoma. 2015;56(11):3216-8
pubmed: 25760636
Blood. 2014 May 8;123(19):2944-52
pubmed: 24591201
J Immunol. 2014 Feb 15;192(4):1597-608
pubmed: 24453250
Blood. 2020 Apr 9;135(15):1214-1218
pubmed: 31961926
Haematologica. 2020 Jul;105(7):1907-1913
pubmed: 31601688
J Clin Oncol. 2016 Oct 20;34(30):3618-3626
pubmed: 27551111
Nat Rev Cancer. 2014 Aug;14(8):517-34
pubmed: 25008267